Nucleic acid sequences of CIITA genes which can be involved in controlling and regulating the expression of genes encoding MHC type II molecules, and their use, in particular as drugs
AssigneeNovImmune S.A.
InventorBernard Mach
Life of this patent
Estimating the term…
Abstract
The present invention relates to nucleic acid sequences which comprise all or part of a nucleic acid sequence of a CIITA gene. These sequences can comprise a sequence which exhibits a transcriptional promoter activity, which activity is, in particular, specifically expressed in one cell type. The sequences can also comprise a coding sequence. Therapeutic and diagnostic applications, in particular relating to disorders in which it is desirable to act on the level at which genes which encode the class II molecules of the major histocompatibility complex (MHC) are expressed.
Claims18
A nucleic acid sequence which comprises all or part of a nucleic acid sequence of a CIITA gene and which is selected from the sequences SEQ ID No. 1, SEQ ID No. 2 and SEQ ID No. 3, and their complementary sequences.
A nucleic acid sequence which comprises the sequence SEQ ID NO.:4, or its complementary sequence.
A nucleic acid sequence which comprises the sequence SEQ ID NO.:6, or its complementary sequence.
A nucleic acid sequence consisting of:
- a) a nucleic acid sequence of SEQ ID No.5;
- or
- b) the complementary sequence of SEQ ID No. 5:
- and which exhibits a transcriptional promoter activity.
A nucleic acid sequence which comprises a sequence selected from:
- a) a nucleic acid sequence which encodes a CIITA polypeptide which consists of the amino acids defined in accordance with SEQ ID NO.:16, and its complementary sequence,
- b) the sequences SEQ ID NO.:7, SEQ ID NO.:8, SEQ ID NO.:10, and SEQ ID NO.:11 and their complementary sequences,
- c) a nucleic acid sequence which encodes an allelic variant of a CIITA polypeptide defined in a).
A method for detecting a mutation in CIITA genes comprising:
- obtaining a biological sample from a patient;
- detecting the presence of at least one mutation in CIITA genes by analyzing nucleic acid sequence in the sample and comparing said nucleic acid sequence from the patient with the wild type sequences SEQ ID NO.:1, SEQ ID NO.:2 and SEQ ID NO.:3.
Dependencies are inferred from the claim text.